For the first time, a clinical study has identified how CBD alters brain function in ways that may correlate with improvements in psychosis.
“A dramatic change toward healthy brain function” was identified though brain MRIs of patients receiving CBD,” said an October 2018 article in Psychiatric News.
“The prospect of a relatively benign, effective antipsychotic medication is extremely encouraging,” said lead researcher Sagnik Bhattacharyya, M.D., Ph.D.
“In contrast to current antipsychotic medications, CBD is well tolerated,” said Dr. Bhattacharyya.
Donald Goff, M.D., vice chair for research in psychiatry at New York University and author of a review article on the risks and benefits of cannabinoids and schizophrenia, told Psychiatric News that:
“Cannabidiol is a very promising drug from which we may learn a lot about better ways to treat psychosis, but this particular study is only one piece of a very complicated puzzle.”
CBD increases anandamide in the body, he said.
The study included 33 subjects clinically at risk for psychosis, divided into a group receiving a single 600 mg dose of CBD and a group receiving placebo.
The brains of another 19 healthy subjects were imaged under otherwise identical conditions without either CBD or placebo to establish a comparative baseline.
Bhattacharyya and colleagues have received a grant for a clinical trial involving 300 patients with multiple dosing over a sustained period of time.
The research was originally published online in JAMA Psychiatry on August 29, 2018.